Christopher Hite

Christopher Hite

Executive Vice President & Vice ChairmanatRoyalty Pharma· In proxies 2021–2025

Pay in FY2025+5% from the year before · Royalty Pharma stock +51.5% the same year

Christopher Hite was paid $1.3M in FY2025 (Dec), up 5%. Royalty Pharma stock rose 51.5% that year.

Pay$100 in the stock at the end of FY20 → $80
Pay is from the Summary Compensation Table of each Royalty Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Royalty PharmaPublic company · 5 yr
    • Executive Vice President & Vice Chairman2021 – Present · 5 yrStock in role +37%
  2. Kailera TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  3. Vera TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  4. Acceleron Pharma Inc.Public company · 1 yr
    • Director2020 – 2021 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?